13-Mar-2026
No headlines found.
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Thu, 26-Feb 7:05 AM ET)
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
Globe Newswire (Wed, 18-Feb 4:01 PM ET)
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
Globe Newswire (Thu, 12-Feb 4:01 PM ET)
Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors
PRNewswire (Wed, 4-Feb 8:54 AM ET)
Globe Newswire (Mon, 26-Jan 5:16 PM ET)
Business Wire (Fri, 23-Jan 8:00 PM ET)
Anika Therapeutics Announces Leadership Transition
Globe Newswire (Thu, 8-Jan 7:00 AM ET)
ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP
Business Wire (Tue, 30-Dec 6:00 PM ET)
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Anika Therapeutics trades on the NASDAQ stock market under the symbol ANIK.
As of March 13, 2026, ANIK stock price declined to $14.20 with 91,481 million shares trading.
ANIK has a beta of 0.95, meaning it tends to be less sensitive to market movements. ANIK has a correlation of 0.08 to the broad based SPY ETF.
ANIK has a market cap of $204.74 million. This is considered a Small Cap stock.
Last quarter Anika Therapeutics reported $31 million in Revenue and $.31 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.37.
In the last 3 years, ANIK traded as high as $29.26 and as low as $7.87.
The top ETF exchange traded funds that ANIK belongs to (by Net Assets): VTI, IWM, AVUV, VXF, IWN.
ANIK has underperformed the market in the last year with a return of -6.6%, while SPY returned +21.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ANIK shares. However, ANIK has outperformed the market in the last 3 month and 2 week periods, returning +48.5% and -1.1%, while SPY returned -2.6% and -3.5%, respectively. This indicates ANIK has been having a stronger performance recently.
ANIK support price is $13.78 and resistance is $14.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANIK shares will trade within this expected range on the day.